Infection and pulmonary vascular diseases consortium: United against a global health challenge
Leveraging the potential of virtual platforms in the post-COVID-19 era, the Infection and Pulmonary Vascular Diseases Consortium (iPVDc), with the support of the Pulmonary Vascular Research Institute (PVRI), launched a globally accessible educational program to highlight top-notch research on inflammation and infectious diseases affecting the lung vasculature. This innovative virtual series has already successfully brought together distinguished investigators across five continents - Asia, Europe, South and North America, and Africa. Moreover, these open global forums have contributed to a comprehensive understanding of the complex interplay among immunology, inflammation, infection, and cardiopulmonary health, especially concerning pulmonary hypertension and related pulmonary disorders. These enlightening discussions have not only heightened awareness about the impact of various pathogenic microorganisms, including fungi, parasites, and viruses, on the onset and development of pulmonary vascular diseases but have also cast a spotlight on co-infections and neglected illnesses like schistosomiasis - a disease that continues to impose a heavy socioeconomic burden in numerous regions worldwide. Thus, the overall goal of this review article is to present the most recent breakthroughs from infectious PVDs as well as bring to light the scientific and educational insights from the 2023 iPVDc/PVRI virtual symposium series, shaping our understanding of these crucial health issues in this more than ever interconnected world.
Authors
- Brian B. Graham (ORCID: https://orcid.org/0000-0001-7541-2585)
- Olga Tura-Ceide (ORCID: https://orcid.org/0000-0003-4334-9790)
- Suellen D. Oliveira (ORCID: https://orcid.org/0000-0002-7654-1909)
- Ana Olga Mocumbi (ORCID: https://orcid.org/0000-0002-9564-2860)
- Ghazwan Butrous (ORCID: https://orcid.org/0000-0002-6640-6332)
- Navneet K. Dhillon (ORCID: https://orcid.org/0000-0001-6582-5757)
- Peter S. Nyasulu (ORCID: https://orcid.org/0000-0003-2757-0663)
- Alexandre Todorovic Fabro (ORCID: https://orcid.org/0000-0002-7687-3161)
- Rudolf K.F. Oliveira (ORCID: https://orcid.org/0000-0002-2252-8119)
- Vinicio de Jesús Pérez (ORCID: https://orcid.org/0000-0001-5532-8247)
- Sharilyn Almodóvar (ORCID: https://orcid.org/0000-0002-4769-1924)
Institutions
- Texas Tech University (US)
- San Francisco General Hospital (US)
- Western Cape Department of Health (ZA)
- University of Illinois Urbana-Champaign (US)
- Medway School of Pharmacy (GB)
- Eduardo Mondlane University (MZ)
- Universidade de São Paulo (BR)
- University of California, San Francisco (US)
- University of the Witwatersrand (ZA)
- University of Kent (GB)
- Stellenbosch University (ZA)
- University of Illinois Chicago (US)
- Centre for Biomedical Network Research on Rare Diseases (ES)
- Institut d'Investigació Biomèdica de Girona (ES)
- University of Kansas Medical Center (US)
- Instituto Nacional de Saúde (MZ)
- Universidade Federal de São Paulo (BR)
- Texas Tech University Health Sciences Center (US)
- Stanford University (US)
Publication Details
- Journal
- Pulmonary Circulation
- Published
- 2024-10-01
- DOI
- https://doi.org/10.1002/pul2.70003
- Citations
- 9
- Primary Topic
- Pulmonary Hypertension Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 3.77
Funders
- Cleveland Clinic
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
- National Institutes of Health
- National Heart, Lung, and Blood Institute